Cytotoxic agents comprising maytansinoids and their therapeutic use

• US 5,208,020 A
• Filed: 07/13/1992
• Issued: 05/04/1993
• Est. Priority Date: 10/25/1989
• Status: Expired due to Term

• Current Assignee: ImmunoGen Incorporated (Abbvie Incorporated)
• Original Assignee: ImmunoGen Incorporated (Abbvie Incorporated)
• Inventors: Blattler, Walter A., Lambert, John M., Chari, Ravi J., Goldmacher, Victor S.
• Primary Examiner(s): Waddell, Frederick E.
• Assistant Examiner(s): Hook, Gregory
• Application Number:
  US07/911,380
• Time in Patent Office: 295 Days
• Field of Search: 424/85.91, 514/229.5, 540/462, 530/390
• US Class Current: 424/181.1
• CPC Class Codes: A61K 31/535 having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• CPC Class Codes: A61K 47/6803 Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
• CPC Class Codes: A61K 47/68033 the drug being a maytansine
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

A cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. A therapeutic agent for killing selected cell populations comprising: (a) a cytotoxic amount of one or more maytansinoids linked to a cell binding agent, and (b) a pharmaceutically acceptable carrier diluent or excipient. A method for killing selected cell populations comprising contacting a cell population or tissue suspected of containing cells from said selected cell population with a cytotoxic amount of a cytotoxic agent comprising one or more maytansinoids linked to a cell binding agent. An N-methyl-alanine-containing ester of maytansinol or an analogue of maytansinol, said N-methyl-alanine-containing ester comprising a linking group capable of linking an N-methyl-alanine-containing maytansinoid ester to a chemical moiety. N-methyl-cysteine-containing ester of maytansinol or an analogue of maytansinol.

Claims

1. A cytotoxic agent comprising one or more maytansinoids linked to a monoclonal antibody or fragment thereof via a disulfide bridge at the C-3, -14, -15, or -20 position of said maytansinoids and wherein said monoclonal antibody or fragment thereof is selective for tumor cell antigens.

2. The cytotoxic agent of claim 1, wherein the one or more maytansinoids is linked to said monoclonal antibody or fragment thereof via a disulfide bridge at the C-3 position of maytansinol.

3. The cytotoxic agent of claim 2, wherein the one or more maytansinoids is an ester of dechloro maytansinol.

4. The cytotoxic agent of claim 2, wherein the one or more maytansinoids is represented by formula (IV):

##STR7## wherein;

Z₀ represents H or SR, wherein R represents methyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl or heterocyclic;

l represents 1, 2 or 3;

y₀ represents Cl or H; and

X₃ represents H or CH₃.

5. The cytotoxic agent of claim 4, wherein R represents methyl.

6. The cytotoxic agent of claim 2, wherein said one or more maytansinoids is N-methyl-N-(3-methyldithiopropanoyl)-L-alanine.

7. A pharmaceutical composition comprising:

(a) one or more maytansinoids linked to a monoclonal antibody or fragment thereof via a disulfide bridge at the C-3, -14, -15 or -20 position of said maytansinoids and wherein said monoclonal antibody or fragment thereof is selective for tumor cell antigens, and

(b) a pharmaceutically acceptable carrier, diluent or excipient.

8. The pharmaceutical composition of claim 7, wherein the one or more maytansinoids is linked to said monoclonal antibody or fragment thereof via a disulfide bridge at the C-3 position of maytansinol.

9. The pharmaceutical composition of claim 7, wherein the one or more maytansinoids is an ester of dechloro maytansinol.

10. The pharmaceutical composition of claim 7, wherein the one or more maytansinoids is represented by formula (IV):

##STR8## wherein;

Z₀ represents H or SR, wherein R represents methyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl or heterocyclic;

l represents 1, 2 or 3;

y₀ represents Cl or H; and

X₃ represents H or CH₃.

11. The pharmaceutical composition of claim 7, wherein R represents methyl.

12. The pharmaceutical composition of claim 7, wherein said one or more maytansinoids is N-methyl-N-(3-methyldithiopropanoyl)-L-alanine.

13. A method for treating cancer sensitive to treatment with said method, said method comprising parenterally administering to a patient in need thereof an effective dose of a composition comprising one or more maytansinoids linked to a monoclonal antibody or fragment thereof via a disulfide bridge at the C-3, -14, -15 or -20 position of said maytansinoids and wherein said monoclonal antibody or fragment thereof is selective for tumor cell antigens.

14. The method for treating cancer of claim 13, wherein the one or more maytansinoids in linked to said monoclonal antibody or fragment thereof via a disulfide bridge at the C-3 position of maytansinol.

15. The method for treating cancer of claim 13, wherein the one or more maytansinoids is an ester of dechloro maytansinol.

16. The method for treating cancer of claim 13, wherein the one or more maytansinoids is represented by formula (IV):

##STR9## wherein;

Z₀ represents H or SR, wherein R represents methyl, linear alkyl, branched alkyl, cyclic alkyl, simple or substituted aryl or heterocyclic;

l represents 1, 2 or 3;

y₀ represents Cl or H; and

X₃ represents H or CH₃.

17. The method for treating cancer of claim 13, wherein R represents methyl.

18. The method for treating cancer of claim 13, wherein said one or more maytansinoids is N-methyl-N-(3-methyldithiopropanoyl)-L-alanine.